A critical vulnerability in COVID-19 immunity has emerged that could reshape therapeutic antibody development and vaccination strategies. The phenomenon occurs when antibodies intended to protect against the virus instead facilitate its entry into immune cells, potentially worsening infections rather than preventing them.
The Coronavirus Immunotherapeutic Consortium analyzed over 400 monoclonal antibodies and discovered that antibody-dependent enhancement requires simultaneous engagement of two distinct cellular pathways. Macrophages proved most susceptible to this enhanced infection, with certain antibodies dramatically increasing viral uptake. Complete blockade of Fc receptors eliminated the enhancement entirely, while ACE2 receptor blocking significantly reduced it. Surprisingly, both potent and weak neutralizing antibodies could trigger enhancement, with the critical factor being the antibody's ability to interfere with spike protein binding to ACE2 receptors.
This dual-receptor mechanism represents a paradigm shift from previous understanding of antibody enhancement in viral infections. Unlike dengue or HIV enhancement patterns, COVID-19 enhancement depends on precise molecular positioning that allows antibodies to simultaneously bridge viral particles to both immune recognition systems and cellular entry points. The finding explains why some therapeutic antibodies showed unexpected clinical outcomes and why certain individuals experienced severe reinfections despite robust antibody responses. Evaluation against Omicron variants revealed reduced enhancement for most antibodies, suggesting viral evolution may have inadvertently mitigated this risk. However, several antibodies showed increased enhancement against Omicron, highlighting the need for continuous monitoring of therapeutic antibody safety profiles as new variants emerge.